Baltimore-based Scanogen develops molecular diagnostic systems that detect infectious-disease biomolecules directly from body fluids, using its proprietary Single Molecule And Rapid Tethering (SMART) technology. The company is focused on a sample-to-answer platform for point-of-care testing, including an assay designed to identify bloodstream-infection pathogens from whole blood within two hours. Scanogen has received more than $20 million in NIH grants and collaborates with Johns Hopkins University and federal agencies in the Washington, D.C., area.
FDA Breakthrough Device Status
compliance_program